21st December 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Baba Ramdev's Divya Pharmacy among 16 firms blacklisted in Nepal

Sixteen Indian Pharma companies including Baba Ramdev’s Divya Pharmacy have been blacklisted by Nepal’s drug regulatory authority over the failure to comply with World Health Organization’s drug manufacturing standards.

Digital Pharma major Partex all set to invest ₹1,000 crore in Uttar Pradesh

Multi-national digital pharma company Partex has shared the desire to invest ₹1,000 crore in Uttar Pradesh. The firm deals with big data and artificial intelligence to aid in drug discovery and development for better outcomes in the healthcare sector.

US FDA issues form 483 to Alembic pharma with five observations

Indian drugmaker Alembic Pharmaceuticals announced on Tuesday that the firm has received a form 483 with 5 observations from the US drug regulatory authority after an inspection of the company’s Solid oral Manufacturing facility at Jarod.

Ashraf Allam appointed as new Global Chief Operating Officer of Cadila Pharma

On Tuesday, Cadila Pharma announced the appointment of Ashraf Allam as the Global Chief Operating Officer. He will be based at Bhat corporate office and will be reporting to Dr. Rajiv Modi (Cadila’s Group Chairman and Managing Director).

Cancer center leaders set uncovered CAR-T makers' struggles

Earlier this year, the US drug health authority moved two CAR-T therapies into earlier large B-cell lymphoma (LBCL) and arranged for a second cell therapy for multiple myeloma. But even after five years of collective measures the biopharma industry is still struggling to ensure smooth and timely access.

Patient's health data is not shared with insurance firms and pharma firms: Govt

The Ayushman Bharat Digital Mission (ABDM) helps the safe exchange of data between intended stakeholders on its network after the individual’s consent and no data is shared with any other firms like pharma or insurance ones without the consent.

US FDA accepts sBLA for priority review to treat patients with special condition of metastatic urothelial cancer

Astellas Pharma Inc., Seagen Tnc. and Merck, have announced that the US FDA has accepted its supplemental Biologics License Applications (sBLAs) for priority review which is related to Padcev and Keytruda indicated for the treatment of special case of metastatic urothelial cancer.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
1
Need Help?
PharmaState Academy
Hello, how can we help you?